The Immune and Endocrine Systems in Chronic Non-cancer Patients Treated With Opioids
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02277080|
Recruitment Status : Enrolling by invitation
First Posted : October 28, 2014
Last Update Posted : March 13, 2020
The primary aim is to investigate the dose and time dependent effects of different opioids on the immune and endocrine systems.
The secondary aim is to investigate whether associations between the function of the immune and endocrine systems and opioid use influence cognitive function, pain and quality of life.
|Condition or disease|
|Pain Opioids Immune System Endocrine System Quality of Life|
|Study Type :||Observational|
|Estimated Enrollment :||104 participants|
|Official Title:||The Immune and Endocrine Systems in Chronic Non-cancer Patients Treated With Opioids: Effects on Cognition, Pain and Quality of Life|
|Actual Study Start Date :||October 2014|
|Estimated Primary Completion Date :||June 2021|
|Estimated Study Completion Date :||June 2022|
These patients should have been treated only with one opioid (morphine, oxycodone, fentanyl, methadone, hydromorphone, tapentadol or tramadol) for more than one month
Chronic non-cancer pain patients not treated with analgesics
- Dose and time dependent effects [ Time Frame: Up to 2.5 years ]Differences on the mean results of endocrine and immunologic blood tests between patients and controls, considering dose and time dependent effects.
- Function of the immune and endocrine systems [ Time Frame: Up to 2.5 years ]Differences on the mean scores of the cognitive tests, pain intensity and quality of life between patients and controls.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02277080
|Principal Investigator:||Per Sjøgren, Proff.||Rigshospitalet, Denmark|